Drug Delivery

Dry Powder Inhalers (DPI)

In vitro APSD, emitted-dose, flow-profile, stability, and modeling studies for dry powder inhaler programs.

NGI, Andersen impactors, dry powder dispersers, APS, Spraytec, high-speed imaging, breathing simulation, HPLC assays, and CFD support matched to powder and device.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-05-17
Request a quoteSubmit a sample

Testing dry powder inhalers

Dry powder inhaler testing connects powder formulation and dose metering with device resistance, patient-generated flow, and measurable aerosol output. USP <601>, USP <1601>, and FDA MDI / DPI / nasal guidance provide the main in vitro framework for emitted dose, APSD, fine-particle dose, and performance linked to stability. These studies support device and formulation decisions when:

  1. APSD from NGI or Andersen impactors compares powder lots, device resistance, and mouthpiece designs under USP <601> and FDA inhalation guidance.
  2. Emitted dose and dose uniformity series quantify capsule, blister, reservoir, and use-life variability under USP <601> and USP <1601>.
  3. Flow-rate dependency studies pair controlled pressure drops or breathing profiles with DPI output for FDA use-condition and ISO 20072 design evidence.
  4. Powder cloud, plume, and high-speed imaging document deagglomeration timing and mouthpiece release behavior for FDA comparability or troubleshooting packages.
  5. Stability pulls repeat APSD, emitted dose, assay, and visual checks after humidity or temperature exposure under ICH Q1A.
  6. CFD-supported studies interpret internal airflow, mouthpiece transport, and deposition sensitivity when FDA engineering rationale is needed before tooling changes.

Use DPI testing when flow, powder cohesion, storage history, or device geometry could affect delivered aerosol performance. Before samples arrive, a defined protocol sets the flow conditions, loading sequence, collection train, assay, and replicate logic for the study.

In vitro test menu for DPI programs

DPI programs typically combine aerodynamic sizing and dose measurements with flow-dependent simulation, imaging, modeling, and stability work. The test set should reflect the development stage, comparator strategy, and regulatory question.

Test method options

MethodStrengthsTradeoffAligned with
APSD and fine-particle dose package
  • Cascade impactor collection quantifies MMAD, GSD, fine-particle dose, and stage recovery under USP <601>.
  • Active-specific assay and mass balance support FDA inhalation submissions and comparator studies.
Requires locked flow conditions, device adapters, and assay readiness before high-value comparisons begin.
USP <601>FDA MDI / DPI / nasal
Emitted dose and use-life delivery series
  • Multi-device sequences measure emitted dose, delivered mass, device retention, and use-life positions under USP <601>.
  • Lot, fill format, and dose-count comparisons support USP <1601> characterization and ISO 20072 design verification.
Dose collection alone cannot explain respirable fraction shifts; pair with APSD when deposition risk matters.
USP <601>USP <1601>ISO 20072
Flow-rate and breathing-profile evaluation
  • Controlled flow and pressure-drop sweeps show how patient effort changes emitted dose and APSD under FDA use-condition framing.
  • Programmable profiles test capsule, blister, and reservoir formats without changing the analytical endpoint.
Profile assumptions drive interpretation; flow, volume, ramp, and resistance targets must be declared in the protocol.
FDA MDI / DPI / nasal
Powder cloud and plume visualization
  • High-speed imaging and optical sizing resolve release timing, cloud shape, and deagglomeration behavior for FDA change-control studies.
  • Mouthpiece or airflow-path variants can be compared under matched flow and trigger settings.
Not every DPI produces a conventional plume; imaging supports interpretation but does not replace dose or APSD.
FDA MDI / DPI / nasal
Stability and humidity-conditioned performance pulls
  • Conditioned samples track emitted dose, APSD, assay, and device function across ICH Q1A storage timepoints.
  • Distribution conditioning can add ASTM D4169 stress before post-stress aerosol performance testing.
Study duration follows storage and pull timing; chamber capacity and analytical scheduling should be planned early.
ICH Q1AASTM D4169
CFD-supported airflow and aerosol transport study
  • Modeling estimates internal flow, powder transport, mouthpiece deposition, and sensitivity to geometry changes for FDA engineering rationale.
  • Measured PSD, dose, or plume data provide validation points for interpreting transport predictions.
CFD supports design decisions; it does not replace measured compendial dose or APSD data.
FDA MDI / DPI / nasal

Setup configurations

Each DPI study is built around the device format, flow dependency, powder handling, and the decision the data need to support. The same inhaler may require different fixtures for APSD, emitted dose, cloud imaging, stability pulls, or CFD validation. Before the first collection run, study planning defines the loading sequence, flow control, conditioning history, assay recovery plan, and replicate structure.

Device interfaces

Mouthpiece adapters, capsule holders, blister piercers, reservoir fixtures, induction ports, and custom mounts matched to device geometry and collection train.

Flow & resistance profiles

Flow rate, pressure drop, inhalation volume, ramp profile, hold time, and breathing-profile assumptions defined for each endpoint.

Powder & dose handling

Powder lot, fill mass, capsule or blister condition, loading sequence, dose count, cleaning interval, and use-life position documented before runs.

Conditioning & stability state

Temperature, RH, storage orientation, preconditioning, and post-stress timing logged when humidity or aging may change powder cohesion.

Replicates & controls

Device count, dose count, blanks, reference devices, and recovery checks sized to the study decision and expected variability.

Quality frame for DPI testing

ARE Labs runs DPI studies within a documented quality system and uses the compendial and regulatory references that most often guide inhalation product testing and device performance reporting.

  • ISO 17025AccreditedLaboratory competence, calibration traceability, method control, and uncertainty contributors.
  • USP <601>AccreditedInhalation aerosols and sprays, including APSD and delivered-dose performance tests.
  • USP <1601>AlignedInhalation product characterization language used where it fits the study.
  • FDA MDI / DPI / nasalAlignedCMC expectations for product quality attributes and device change control.

Key data outputs & reporting

Each DPI program receives endpoint-specific datasets that connect the device setup with measured output. Deliverables may include APSD tables, emitted-dose statistics, comparisons across flow conditions, powder cloud files, assay recovery, and QA/QC controls. Reports are prepared for development review, method justification, comparability packages, or interpretation of stability trends. When the program includes model validation, comparator work, or storage pulls, extended deliverables provide the supporting appendices.

Primary outputs

  • APSD stage mass, MMAD, GSD, fine-particle dose or fraction, throat deposition, device retention, and active-specific assay results.
  • Emitted dose, delivered mass, dose uniformity, use-life statistics, mean, SD, and %RSD by device, lot, or flow condition.
  • Flow-rate or breathing-profile results, including pressure drop, inhalation volume, ramp assumptions, and interface notes.
  • Powder cloud images, plume observations, high-speed video exports, and CFD velocity or transport maps where included.

Deliverables

#FormatContents
01PDF reportProtocol summary, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsStage mass, dose statistics, flow profiles, and assay tables.
03Images / videoPowder cloud frames, plume files, overlays, and high-speed video exports.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side APSD, dose, and flow-condition summaries for reference, predicate, or design-change review.
  • Stability trend pack — Timepoint tables and figures showing dose, APSD, assay, and device-function drift after conditioning.
  • Model validation notes — CFD assumptions, boundary conditions, mesh notes, and measured data used to ground airflow outputs.

QA / QC & data integrity

Each DPI study includes a QA/QC plan matched to the selected endpoints, powder handling, assay, and regulatory frame. Controls run alongside sample collection so dose, particle, and flow data remain traceable from sample receipt through the final report. Method deviations, invalid runs, and sources of uncertainty are documented directly, not buried in summary tables.

Blanks, background checks, comparator devices, or reference runs defined by endpoint and collection train.

Flow meters, balances, impactor stages, timers, imaging scales, and breathing simulators checked or calibrated before use.

Assay controls for HPLC, ELISA, qPCR, or ddPCR, including calibration standards and recovery checks when required.

Chain of custody for devices, powders, capsules, blisters, collected stages, filters, extracts, raw files, and analyst observations.

Predefined acceptance criteria, replicate rules, deviation handling, cleaning intervals, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

DPI development and regulatory teams often ask the same questions when scoping a study: which endpoints to combine, how flow conditions are selected, how many devices and powder lots are needed, and what documentation will be delivered. Most DPI programs also require at least one decision about a custom fixture, loading, conditioning, or assay. Those details are best resolved during protocol planning, before testing begins.

Q.Which DPI test should I start with?
A.When delivery performance is the main question, start with emitted dose and APSD. Add flow-profile testing, imaging, stability, or CFD when the device mechanism or storage history may help explain the result.
Q.Can ARE Labs test multiple DPI flow rates?
A.Yes. DPI protocols can define flow rates, pressure drops, inhalation volumes, ramp profiles, or breathing profiles. These choices matter because inspiratory effort can change deagglomeration, emitted dose, and APSD.
Q.How many inhalers or doses are needed?
A.The number of devices, powder lots, doses, use-life positions, and replicates depends on the endpoint and expected variability. We define these counts during protocol development.
Q.What data will I receive?
A.Deliverables can include APSD tables, emitted-dose statistics, flow-profile data, assay results, powder cloud images, CFD outputs, deviations, QA/QC records, and a written report.
Q.Does this certify or approve a DPI product?
A.No. ARE Labs provides defined in vitro aerosol, dose, stability, and modeling data that can support development and regulatory documentation. Product approval, clinical studies, and full submission management are separate scopes.

Standards & guidance

DPI test programs at ARE Labs draw on the compendial, consensus, and regulatory references used to characterize inhalation products. Accredited scopes are identified as accredited; other references are described as aligned or conformant where applicable. The rows below cover the standards and guidance clusters most often cited for DPI aerosol performance, emitted dose, flow-dependent delivery, stability support, and engineering rationale.

Inhalation & Drug Delivery - Accredited

USP <601>

Inhalation aerosols and sprays: APSD, delivered dose, and performance quality testsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Inhalation product characterization language used for dose and performance studiesView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for inhalation products, comparability, device changes, and CMC supportView standard ->Inhalation & Drug Delivery - Aligned

ISO 20072

Aerosol drug delivery device design verification and dose delivery characteristicsView standard ->QA & Regulatory - Aligned

ICH Q1A

Stability storage conditions, pull timing, and trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress aerosol performance evaluationView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Core DPI test for APSD, MMAD, GSD, fine-particle dose, and flow-dependent respirable fraction.Read more ->Test

Dose Uniformity & Emitted Dose

Measures actuation, capsule, blister, reservoir, lot, and use-life consistency before interpreting APSD shifts.Read more ->Test

Spray Pattern & Plume Geometry

Documents powder cloud, release timing, and mouthpiece emission behavior when DPI geometry changes affect delivery.Read more ->Test

Breathing Simulation Testing

Adds controlled inspiratory profiles, pressure drops, and flow ramps for flow-sensitive DPI output studies.Read more ->Test

Computational Fluid Dynamics (CFD)

Supports internal airflow, mouthpiece transport, deposition interpretation, and fixture design when DPI geometry changes.Read more ->Test

Stability & Accelerated Aging

Pairs humidity or storage pulls with DPI dose, APSD, assay, and device-function trending.Read more ->